Ascelia Pharma

Dagens aktienyheder 11/02-2026: Danish Aerospace Company og Ascelia Pharma

We have only made minor adjustments to our Ascelia Pharma one-pager following the FY 2025 results. The FDA timeline for Orviglance was already known ahead of the report, with the NDA accepted for review in November 2025 and a PDUFA decision date confirmed for 3 July 2026. The FY 2025 results, therefore, contained no major surprises, and our investment case remains largely unchanged with only minor adjustments. Notably, management expressed increased confidence on partnering in connection with the report. CEO Magnus Corfitzen stated that the partnering process continues to progress, with multiple potential partners demonstrating strong strategic interest.

Today, we hosted an event with Magnus Corfitzen, CEO of Ascelia Pharma. The presentation focused on the financial results and regulatory milestones achieved during the fourth quarter, with particular emphasis on the investment case for Orviglance. The event concluded with a Q&A session, with discussion centred on the status and outlook regarding potential partners.

Ascelia Pharma is expected to release its full-year 2025 results on 5 February 2026. Join us for a live presentation with CEO Magnus Corfitzen from Ascelia Pharma the following day at 13:00, where he will present the financial results for 2025 and provide an update on the company’s latest developments.

Mød ledelsen i Gabriel Holding, Mdundo, Skjern Bank og Ascelia Pharma og stil spørgsmål i dagens investorpræsentationer

This morning, Ascelia Pharma published its Q4 2025 and full-year results. Beyond the NDA acceptance, the quarter was operationally quiet. Ascelia filed a new patent application. Management reiterates that the runway extends into Q4 2026, and that partner conversations are progressing.

I dagens Morgenbørs ser vi ind i en flad åbning på dagen i Europa. Software sell-off spreder sig til resten af AI-temaet. Herhjemme fokus på bygen af store danske regnskaber.

Dagens aktienyheder 05/02-2026: Gubra, Danske bank, Ascelia Pharma

Dagens aktienyheder 22/01-2026: WindowMaster, Agillic, GomSpace, Rovsing, Ascelia Pharma, Scandinavian Medical Solutions og Flügger

Dagens aktienyheder med Scandinavian Medical Solutions, SP Group, GreenMobility A/S og Ascelia Pharma AB

Read the latest Ascelia Pharma one-pager following the FDA’s acceptance of the Orviglance new drug application (NDA) for review and the confirmation of an FDA decision date by 3 July 2026. This marks the official start of the regulatory review period and provides a clear timeline toward a potential first approval for the first gadolinium-free liver MRI contrast agent for patients with severe kidney impairment.